Anti-Human CD131/CSF2RB Reference Antibody (CSL 311, RUO) (HW498016)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HW498016
Description	Anti-Human CD131/CSF2RB (CSL 311) (HW498016) is a research-grade recombinant antibody targeting CD131. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	CSL 311
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Cytokine receptor common subunit beta, IL3RB, IL5RB, CDw131, CD131, CSF2RB, GM-CSF/IL-3/IL-5 receptor common beta subunit
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P32927
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	CSL-311, CSL311, CSL311
Background	Cytokine receptor common subunit beta (CD131/CSF2RB) is a ~97 kDa protein. Cell surface receptor that plays a role in immune response and controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells. Acts by forming an heterodimeric receptor through interaction with different partners such as IL3RA, IL5RA or CSF2RA. In turn, participates in various signaling pathways including interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor/CSF2 pathways. In unstimulated conditions, interacts constitutively with JAK1 and ligand binding leads to JAK1 stimulation and subsequent activation of the JAK-STAT pathway. 1. Tavernier, J. et al. (1992) Proceedings of the National Academy of Sciences of the United States of America 89, 7041-5. PMID: 1495999 2. Ogata, N. et al. (1998) Blood 91, 2264-71. PMID: 9516124
Note	For research use only. Not suitable for clinical or therapeutic use.